167 related articles for article (PubMed ID: 18212102)
1. Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Dekhtyar T; Ng TI; Lu L; Masse S; DeGoey DA; Flosi WJ; Grampovnik DJ; Klein LL; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2008 Apr; 52(4):1337-44. PubMed ID: 18212102
[TBL] [Abstract][Full Text] [Related]
2. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
[TBL] [Abstract][Full Text] [Related]
4. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
[TBL] [Abstract][Full Text] [Related]
5. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
6. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
[TBL] [Abstract][Full Text] [Related]
7. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
Doyon L; Tremblay S; Bourgon L; Wardrop E; Cordingley MG
Antiviral Res; 2005 Oct; 68(1):27-35. PubMed ID: 16122817
[TBL] [Abstract][Full Text] [Related]
9. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
10. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
[TBL] [Abstract][Full Text] [Related]
11. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
[TBL] [Abstract][Full Text] [Related]
12. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
[TBL] [Abstract][Full Text] [Related]
13. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
16. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
[TBL] [Abstract][Full Text] [Related]
17. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ
Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694
[TBL] [Abstract][Full Text] [Related]
18. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
Schmit JC; Ruiz L; Clotet B; Raventos A; Tor J; Leonard J; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1996 Aug; 10(9):995-9. PubMed ID: 8853733
[TBL] [Abstract][Full Text] [Related]
19. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
20. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
